Sarepta Therapeutics (SRPT)

• Market cap: $5.77B
• 1 day: 2.55%
• 5 days: 4.65%
• 1 month: -2.23%
• 3 months: -45.48%
• 6 months: -51.17%
• Year to date: -49.71%
• 1 year: -50.73%
• 5 years: -47.06%
• 10 years: 411.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Employees: 1,372

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

38% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]

21% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 63

15% more call options, than puts

Call options by funds: $211M | Put options by funds: $184M

2.98% more ownership

Funds ownership: 90.04% [Q3] → 93.02% (+2.98%) [Q4]

1% more funds holding

Funds holding: 452 [Q3] → 457 (+5) [Q4]

0% less capital invested

Capital invested by funds: $10.7B [Q3] → $10.7B (-$26.8M) [Q4]

1% less repeat investments, than reductions

Existing positions increased: 155 | Existing positions reduced: 156

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $75 20% upside
• Avg. target: $122 95% upside
• High target: $183 193% upside

9 analyst ratings

• positive: 5 56%
• neutral: 4 44%
• negative: 0 0%

Piper Sandler Biren Amin 22% 1-year accuracy 6 / 27 met price target	76% upside $110	Overweight Maintained	21 Apr 2025
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 187 met price target	20% upside $75	Neutral Reiterated	16 Apr 2025
Morgan Stanley Matthew Harrison 43% 1-year accuracy 10 / 23 met price target	192% upside $182	Overweight Maintained	11 Apr 2025
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target	84% upside $115	Overweight Initiated	11 Apr 2025
Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target	193% upside $183	Buy Maintained	3 Apr 2025